SEARCH RESULT

Total Matching Records found : 977

Prices of key Drugs to be cut by up to half-Sushmi Dey

-The Business Standard NPPA to soon notify prices in line with new pharma pricing policy Some key cancer Drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according...

More »

We trust indian manufacturing norms: USFDA -Divya Rajagopal

-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic Drugs, the statement, by USFDA's spokesman Chris Kelly in an...

More »

SC ‘very serious’ tag on Ranbaxy charges-R Balaji

-The Telegraph New Delhi: The Supreme Court today observed that even if there was a grain of truth in the charges that Ranbaxy was supplying adulterated Drugs, it was a "very, very serious matter" but refrained from issuing any orders till it received "prima facie material". The court said that drug-testing standards in the US were different from those in India, and what was happening in America might not necessarily be happening...

More »

Hospitals, chemists to wait for regulatory word on Ranbaxy

-PTI Drug regulator DGCI is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drug makers, but says it remains confident of the quality standards of Indian medicines despite concerns raised by US authorities over some of Ranbaxy's products. While the company continues to assert that its Drugs meet all regulatory standards, a few hospitals and pharmacies have adopted a cautious stand on use of its products. However, a majority...

More »

PIL in apex court against Ranbaxy

-The Telegraph The Supreme Court today refrained from passing any order on a plea for early listing of a PIL that had sought closure of pharmaceutical giant Ranbaxy, recently penalised by US authorities for allegedly supplying adulterated and substandard Drugs. The public interest petition sought registration of criminal cases under the penal code and also the Drugs and Cosmetics Act, 1947, against company officials for allegedly cheating millions of patients in the...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close